Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21).

Autor:	Han SY; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN., Mrózek K; Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Voutsinas J; Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Wu Q; Clinical Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Morgan EA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Vestergaard H; Mastocytosis Center and.; Department of Hematology, Odense University Hospital, Odense, Denmark., Ohgami R; Department of Pathology, Stanford University, Stanford, CA., Kluin PM; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Kristensen TK; Mastocytosis Center and.; Department of Pathology, Odense University Hospital, Odense, Denmark., Pullarkat S; Department of Pathology, University of California, Los Angeles, CA., Møller MB; Mastocytosis Center and.; Department of Pathology, Odense University Hospital, Odense, Denmark., Schiefer AI; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria., Baughn LB; Division of Hematopathology, Mayo Clinic, Rochester, MN.; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN., Kim Y; Department of Pathology, City of Hope National Medical Center, Duarte, CA., Czuchlewski D; Department of Pathology, University of New Mexico, Albuquerque, NM., Hilberink JR; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Horny HP; Institute of Pathology, Ludwig-Maximilian University, Munich, Germany., George TI; Department of Pathology, University of New Mexico, Albuquerque, NM.; Department of Pathology, University of Utah, Salt Lake City, UT., Dolan M; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN., Ku NK; Department of Pathology, University of California, Los Angeles, CA., Arana Yi C; Department of Pathology, University of New Mexico, Albuquerque, NM., Pullarkat V; Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA., Kohlschmidt J; Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Salhotra A; Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA., Soma L; Clinical Reseach Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA., Bloomfield CD; Comprehensive Cancer Center, The Ohio State University, Columbus, OH., Chen D; Division of Hematopathology, Mayo Clinic, Rochester, MN., Sperr WR; Division of Hematology and Hemostaseology, Department of Internal Medicine I, and.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Marcucci G; Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA., Cho C; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College; New York, NY., Akin C; Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Michigan, MI., Gotlib J; Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA., Broesby-Olsen S; Mastocytosis Center and.; Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis, Odense, Denmark., Larson M; Division of Hematology, Oncology and Cell Therapy, Rush University, Chicago, IL., Linden MA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN., Deeg HJ; Clinical Reseach Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA., Hoermann G; Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.; Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck, Innsbruck, Austria., Perales MA; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Medicine, Weill Cornell Medical College; New York, NY., Hornick JL; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Litzow MR; Department of Internal Medicine and.; Division of Hematology, Mayo Clinic, Rochester, MN., Nakamura R; Division of Hematology and HCT, City of Hope National Medical Center, Duarte, CA., Weisdorf D; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN., Borthakur G; Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX; and., Huls G; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Valent P; Division of Hematology and Hemostaseology, Department of Internal Medicine I, and.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Ustun C; Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN.; Division of Hematology, Oncology and Cell Therapy, Rush University, Chicago, IL., Yeung CCS; Clinical Reseach Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, WA.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2021 May 25; Vol. 5 (10), pp. 2481-2489.
DOI:	10.1182/bloodadvances.2020003605
Abstrakt:	Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, ∼40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21). (© 2021 by The American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu